Discovery of N-Substituted Oseltamivir Derivatives as Potent and Selective Inhibitors of H5N1 Influenza Neuraminidase
Citations Over TimeTop 10% of 2014 papers
Abstract
To discover group-1-specific neuraminidase (NA) inhibitors that are especially involved in combating the H5N1 virus, two series of oseltamivir derivatives were designed and synthesized by targeting the 150-cavity. Among these, compound 20l was the most potent N1-selective inhibitor, with IC50 values of 0.0019, 0.0038, and 0.0067 μM against NAs from three H5N1 viruses. These values are better than those of oseltamivir carboxylate. Compound 32 was another potent N1-selective inhibitor that exhibited a 12-fold increase in activity against the H274Y mutant relative to oseltamivir carboxylate. Molecular docking studies revealed that the 150-cavity was an auxiliary binding site that may contribute to the high selectivity of these compounds. The present work is a significant breakthrough in the discovery of potent group-1-specific neuraminidase inhibitors, which may be further investigated for the treatment of infection by the H5N1 virus.
Related Papers
- → Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and Zanamivir(2001)148 cited
- → An iron carbonyl approach to the influenza neuraminidase inhibitor oseltamivir(2007)73 cited
- → Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor(2020)7 cited
- → Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia(2003)12 cited
- → Another neuraminidase inhibitor proves its worth against influenza(1999)